Arrowhead Pharmaceuticals Files 8-K Report
Ticker: ARWR · Form: 8-K · Filed: Sep 2, 2025 · CIK: 879407
Sentiment: neutral
Topics: material-agreement, financials, filing
Related Tickers: ARWR
TL;DR
ARWR filed an 8-K today, looks like a material agreement and financials are in. Details TBD.
AI Summary
On September 2, 2025, Arrowhead Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the entry into a material definitive agreement and the submission of financial statements and exhibits. Specific details of the agreement or financial figures were not provided in the excerpt.
Why It Matters
This filing indicates significant corporate activity, potentially involving new agreements or financial disclosures that could impact investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not, in itself, indicate any immediate or specific risks.
Key Players & Entities
- Arrowhead Pharmaceuticals, Inc. (company) — Registrant
- 0000879407-25-000004 (filing_id) — Accession Number
- September 2, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 177 E. Colorado Blvd , Suite 700 , Pasadena , CA 91105 (address) — Principal Executive Offices
- 626-696-4702 (phone_number) — Business Phone
FAQ
What is the nature of the material definitive agreement entered into by Arrowhead Pharmaceuticals?
The provided excerpt does not specify the details of the material definitive agreement.
What financial statements and exhibits are being filed with this 8-K?
The excerpt confirms that financial statements and exhibits are being filed, but does not list their specific contents.
When was the earliest event reported in this 8-K filing?
The earliest event reported is September 2, 2025, which is also the date of the report.
What is Arrowhead Pharmaceuticals' principal executive office address?
Arrowhead Pharmaceuticals' principal executive office is located at 177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105.
What is Arrowhead Pharmaceuticals' fiscal year end?
Arrowhead Pharmaceuticals' fiscal year ends on September 30.
Filing Stats: 616 words · 2 min read · ~2 pages · Grade level 13.8 · Accepted 2025-09-02 16:02:33
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ARWR The Nasdaq Global Select
- $200 million — on activities. The Company will receive $200 million as an upfront payment and is eligible t
- $2 billion — ayment and is eligible to receive up to $2 billion in potential development, regulatory an
Filing Documents
- arwr-20250902.htm (8-K) — 30KB
- arwr-202509028kex991.htm (EX-99.1) — 18KB
- ghvnqo5ppwcq000001.jpg (GRAPHIC) — 49KB
- 0000879407-25-000004.txt ( ) — 237KB
- arwr-20250902.xsd (EX-101.SCH) — 2KB
- arwr-20250902_lab.xml (EX-101.LAB) — 22KB
- arwr-20250902_pre.xml (EX-101.PRE) — 13KB
- arwr-20250902_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement Exclusive licensing and collaboration agreement On September 2, 2025, Arrowhead Pharmaceuticals, Inc. (the "Company") entered into an Exclusive License and Collaboration Agreement (the "Agreement") with Novartis Pharma AG, a company organized under the laws of Switzerland ("Novartis"). Under the Agreement, Novartis will receive an exclusive license for ARO-SNCA, a preclinical stage investigational RNA interference ("RNAi") therapeutic being developed by the Company as a potential treatment of Parkinson's Disease, and other synucleinopathies, and for other additional collaboration targets utilizing the Company's proprietary Targeted RNAi Molecule platform. The Company will conduct and complete all activities through the preclinical stages of ARO-SNCA, and Novartis will be wholly responsible for clinical development, manufacturing, and commercialization activities. The Company will receive $200 million as an upfront payment and is eligible to receive up to $2 billion in potential development, regulatory and sales milestones, and is further eligible to receive tiered royalties up to the low double digits on net product sales. The transactions contemplated under the Agreement are subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The description of the Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending September 30, 2025.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 2, 2025. 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: September 2, 2025 ARROWHEAD PHARMACEUTICALS, INC. By: /s/ Daniel Apel Daniel Apel Chief Financial Officer